A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
A phase 2 trial of Telisotuzumab adizutecan in advanced solid tumours, run by AbbVie, now recruiting.
Overview
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan is a phase 2 interventional study registered as NCT07196644 by AbbVie, with 100 participants planned, started 2025-12-01 and due to reach its primary completion in 2030-12. Interventions recorded: Telisotuzumab Adizutecan.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialTrial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Shares AbbVie (incl. ImmunoGen, Capstan), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.